CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma - Wikidata - awgldk - TriplyDB

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

http://www.wikidata.org/entity/Q28298277

about

Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties The potential of GPNMB as novel neuroprotective factor in amyotrophic lateral sclerosis Genomic analysis of wig-1 pathways Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Marine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Gene expression profiling of alveolar soft-part sarcoma (ASPS).Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas.Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.Targeted overexpression of osteoactivin in cells of osteoclastic lineage promotes osteoclastic resorption and bone loss in mice.Genomic profiling of rectal adenoma and carcinoma by array-based comparative genomic hybridization Inhibition of Phosphatase Activity Follows Decline in Sulfatase Activity and Leads to Transcriptional Effects through Sustained Phosphorylation of Transcription Factor MITF.Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1.IBC's 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5-8, 2011, San Diego, CA.Candidate genes contributing to the aggressive phenotype of mantle cell lymphoma.Osteoactivin/HGFIN: is it a tumor suppressor or mediator of metastasis in breast cancer?Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly invasive gene signature.Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB.Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma Novel therapeutics for melanoma.Marine-sourced anti-cancer and cancer pain control agents in clinical and late preclinical development.Marine Antibody-Drug Conjugates: Design Strategies and Research Progress.Emerging therapeutic targets in breast cancer bone metastasis.Investigational antibody-drug conjugates for hematological malignancies.Investigational antibody drug conjugates for solid tumors.The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.Using antibodies to target cancer therapeutics.Drug-conjugated antibodies for the treatment of cancer.Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).Emerging formats for next-generation antibody drug conjugates.Knocking down glycoprotein nonmetastatic melanoma protein B suppresses the proliferation, migration, and invasion in bladder cancer cells.Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.Osteoactivin Promotes Migration of Oral Squamous Cell Carcinomas.

P2860

Q24324012-D4A8A930-82EC-4286-9665-91C5D652EF9E Q24624489-3D492AF3-282A-4B9D-A9C5-EE202FF3955B Q26784048-E6DA98A2-842B-46C8-AF46-DDE97F2E8A8B Q27321658-D4ED6395-6646-4202-8EBB-8B70E17A1689 Q28117892-E560053A-2164-48F8-A1A6-406F828785B8 Q28732207-371CCE4F-2264-48B2-9E9F-F87457D7DA2E Q33311571-143026F9-2291-47EC-AD06-43C87F1D2EDC Q33359943-DD2973AA-CD67-4DF5-AFB7-B462D735EB5A Q33400116-DE78A500-DC33-406A-8599-B77888EC93C0 Q33687487-D7C4A193-303D-48FC-A51F-CECECAD876F1 Q33891014-07FF49A7-1972-4367-98AF-2D5585801925 Q34247178-9BBF23DF-701C-41E5-AEE8-3D136FD0C1F7 Q34480042-8B3B712C-1556-4612-83FF-D4172B21D3A6 Q34522141-658F542D-16CF-4FB7-9943-BA640E6697D7 Q34792334-57B541F9-E525-4AA8-A9F3-ABC11D273094 Q34977047-F0146F7F-0025-4271-AA2F-538B2576B7AC Q35058891-D3142C9F-70DD-46F1-A642-3AC7935AD24A Q35992493-596B8E23-5946-4CA4-A30D-8D2245BA4DA1 Q36315020-AA71E25F-C221-4A11-9B9E-504692330845 Q36465274-6503B306-EEF7-4373-8D17-0B9F16BAB2DB Q36738000-557D471D-8A8C-44E8-A46F-486B268B72D0 Q36934332-4126A86F-1E2D-4910-971B-75518F9D0C24 Q36961713-C65AFB0F-C340-44F6-A0EA-702CFC145056 Q37014479-657C683C-4358-4869-BA1A-8C75BE669744 Q37193373-2A539C7A-F157-4826-9ED8-C7F57B513079 Q37329160-7BD1F1F7-DD5E-4597-9927-9D8B3595BD83 Q37508041-DA37B652-5704-4FBB-8ADF-342E32B38AB4 Q37566220-DE9336A6-6E17-4883-9C22-C7E5144F369A Q37628646-02738447-019F-4D50-9826-8DAA03D5A87F Q37658767-E78F8D63-9B3D-45DE-996B-2A3A7BCE4811 Q37818256-890CEE5F-E530-4B9E-B927-FAC58365B888 Q37877745-B71600EA-D3CB-47F4-8F56-AEBCF2CB1FC4 Q37974330-3CE4950E-556F-4D25-90C7-E7B0D860C548 Q38014920-87A79ABC-5A1B-4C70-B169-4BF268C1A45F Q38061647-28933786-2FE0-4EFA-9C26-553BA59D3837 Q38185304-9D94D9F3-E065-4524-B03F-3DF1754DFEEF Q38386705-763FE48E-AA88-48A7-A3CC-0CB6D7A629CE Q38706037-813BEC05-AA68-494C-9BD7-DAFFC75935FE Q38707852-E802F19C-794E-4346-9BB3-6505CA56F539 Q38814412-DB73CA18-9C12-4CD1-9224-B8B419F2DD09

P2860

CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma

http://www.wikidata.org/entity/Q28298277

description

2006 nî lūn-bûn

@nan

2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

CR011, a fully human monoclona ...... for the treatment of melanoma

@ast

CR011, a fully human monoclona ...... for the treatment of melanoma

@en

CR011, a fully human monoclona ...... for the treatment of melanoma

@nl

type

label

CR011, a fully human monoclona ...... for the treatment of melanoma

@ast

CR011, a fully human monoclona ...... for the treatment of melanoma

@en

CR011, a fully human monoclona ...... for the treatment of melanoma

@nl

prefLabel

CR011, a fully human monoclona ...... for the treatment of melanoma

@ast

CR011, a fully human monoclona ...... for the treatment of melanoma

@en

CR011, a fully human monoclona ...... for the treatment of melanoma

@nl

P1433

Q28298277-0F5000C2-0067-4FC9-854E-DBDBFDE15F14

P1476

Q28298277-6A4F02BA-838E-4D87-BAF7-DF2D50F53A96

P2093

Q28298277-0814BECE-58DE-4D2A-88B8-8A791335D66E

Q28298277-0E4EF340-184C-4DFC-B2EF-3B38DC07A96F

Q28298277-159B43C3-0969-4DDE-883B-C95ABB8FEFBC

Q28298277-1C111BB5-B7B9-496B-8F00-286D08237915

Q28298277-1FA8702F-04C7-44A0-8B59-E4EA5C2400F6

Q28298277-24446073-DD45-4A99-9F3D-70DED1355A8F

Q28298277-482537DD-3185-4622-BBD7-3B5C3013BE8F

Q28298277-535B1D6A-7A3A-4811-99E4-B0D4400DE5F0

Q28298277-57ADB35A-5223-4FEE-92BC-2A211986149C

Q28298277-659C32BB-9F8F-433A-AE52-423C0D088CE5

P304

Q28298277-DD4A5380-F6ED-4E09-8B4A-4967A5653193

P31

Q28298277-1E5E64FD-E801-4865-87AC-F9AE03C0E933

P3181

Q28298277-6D5749CC-5CDC-4B46-B8A4-0053AD23974B

P356

Q28298277-C03B0032-719C-4DF7-B86E-1C2E819E23F5

P407

Q28298277-3D11A1A7-2ABC-45FA-9CED-71694AFC9CA6

P433

Q28298277-32EF4452-9EAD-481B-964E-F322495CC7A0

P478

Q28298277-0457FE6C-CBEB-40B7-85F3-7AB6F2BEC406

P577

Q28298277-89FC912B-04B2-4706-AE45-127F769F93B0

P5875

Q28298277-4037AF80-7928-478C-93A4-661EEE33CC15

P698

Q28298277-A8D7636D-6EBE-4B45-B900-75A3D37E9D06

P921

Q28298277-C2D6E2C2-ECF5-4DB1-88F4-947464F49B68

P3181

P356

1078-0432.CCR-05-2018

P1433

Clinical Cancer Research

P1476

CR011, a fully human monoclona ...... for the treatment of melanoma

@en

P2093

Bing Kuang

http://www.w3.org/2001/XMLSchema#string

Craig S Hackett

http://www.w3.org/2001/XMLSchema#string

Damon L Meyer

http://www.w3.org/2001/XMLSchema#string

Denise A McCabe

http://www.w3.org/2001/XMLSchema#string

Ferenc L Boldog

http://www.w3.org/2001/XMLSchema#string

Gadi Gazit-Bornstein

http://www.w3.org/2001/XMLSchema#string

Henri S Lichenstein

http://www.w3.org/2001/XMLSchema#string

John Herrmann

http://www.w3.org/2001/XMLSchema#string

John R MacDougall

http://www.w3.org/2001/XMLSchema#string

Kam Fai Tse

http://www.w3.org/2001/XMLSchema#string

P304

1373-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2310821

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-05-2018

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7288304

http://www.w3.org/2001/XMLSchema#string

P698

16489096

http://www.w3.org/2001/XMLSchema#string

P921